Abstract
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder affecting reproductive-aged women and is often accompanied by insulin resistance and hyperandrogenism. Metformin, a first-line antidiabetic agent, has been widely used in the treatment of PCOS due to its ability to improve insulin sensitivity, regulate menstrual cycles, reduce androgen levels, and promote ovulation. This literature review aims to critically evaluate and synthesize previous research findings on metformin and the influence of genetic and metabolic factors on individual responses in PCOS patients. Nine clinical studies published in the last five years were analyzed. The findings indicate that metformin consistently improves hormonal and metabolic parameters, particularly in overweight or insulin-resistant patients. Combination therapies, such as metformin with pioglitazone, liraglutide, or exenatide, were shown to be more effective than monotherapy in managing metabolic dysfunction and reproductive abnormalities. However, gastrointestinal side effects and interindividual variability in therapeutic response remain significant challenges. These results suggest that personalized treatment strategies based on patient phenotype and tolerance may optimize outcomes. Further research is needed to establish predictive markers and refine therapeutic regimens for long-term PCOS management.
References
Akhtar, N., Banu, H., Morshed, M. S., Sultana, T., Begum, A., & Hasanat, M. (2021). Effects of metformin on polycystic ovary syndrome: a randomized, double-blind, placebo-controlled study. IMC Journal of Medical Science, 15(2), 1–12. https://doi.org/10.3329/imcjms.v15i2.55808
Attia, G. M., Almouteri, M. M., & Alnakhli, F. T. (2023). Role of Metformin in Polycystic Ovary Syndrome (PCOS): Related Infertility. Cureus, 15(8). https://doi.org/10.7759/cureus.44493
Kshatri, J. S., Satpathy, P., Sharma, S., Bhoi, T., Mishra, S. P., & Sahoo, S. S. (2022). Health research in the state of Odisha, India: A decadal bibliometric analysis (2011‑2020). Journal of Family Medicine and Primary Care, 6(2), 169–170. https://doi.org/10.4103/jfmpc.jfmpc
Ma, R. L., Deng, Y., Wang, Y. F., Zhu, S. Y., Ding, X. S., & Sun, A. J. (2021). Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal, 134(23), 2882–2889. https://doi.org/10.1097/CM9.0000000000001712
Pedersen, A. J. T., Stage, T. B., Glintborg, D., Andersen, M., & Christensen, M. M. H. (2018). The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic and Clinical Pharmacology and Toxicology, 122(2), 239–244. https://doi.org/10.1111/bcpt.12874
Peng, Q., Chen, X., Liang, X., Ouyang, J., Wang, Q., Ren, S., Xie, H., Wang, C., Sun, Y., Wu, X., Liu, H., Hei, C., Sun, M., Chang, Q., Liu, X., Li, G., & He, R. (2023). Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. Frontiers in Endocrinology, 14(January), 1–10. https://doi.org/10.3389/fendo.2023.1070264
Wen, Q., Hu, M., Lai, M., Li, J., Hu, Z., Quan, K., Liu, J., Liu, H., Meng, Y., Wang, S., Wen, X., Yu, C., Li, S., Huang, S., Zheng, Y., Lin, H., Liang, X., Lu, L., Mai, Z., … Ma, H. (2022). Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: A three-armed randomized controlled trial. Human Reproduction, 37(3), 542–552. https://doi.org/10.1093/humrep/deab272
Wiweko, B., & Susanto, C. (2017). The Effect of Metformin and Cinnamon on Serum Anti-Mullerian Hormone in Women Having PCOS: A Double-Blind, Randomized, Controlled Trial. Journal of Human Reproductive Sciences, 10(1), 31–36. https://doi.org/10.4103/jhrs.JHRS_90_16
Xing, C., Zhao, H., Zhang, J., & He, B. (2022). Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Frontiers in Endocrinology, 13(August), 1–12. https://doi.org/10.3389/fendo.2022.945609
Zhao, H., Zhang, J., Xing, C., Cheng, X., & He, B. (2024). Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. Journal of Ovarian Research, 17(1), 1–12. https://doi.org/10.1186/s13048-024-01367-7
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Shabina Putri Alliya, Anggi Isnaini, Vian Saltiel Harefa, Dafni Aisyah Fariby, Najwa Adella Feriska, Falesya Jovanka Athallah, Anisa Puja Ningrum, Daniah Atikah, Primayanti Nurul Ilmi